Pravastatin: An Antithrombotic Effect Independent of the Cholesterol-lowering Effect

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Thrombosis and Haemostasis

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1055/s-0037-1613893PMID 10823263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.

  1999influential reference
• Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.

  1999cited by this paper
• The anti-thrombotic effects of statins.

  1999influential reference
• The anti-thrombotic effects of statins.

  1999cited by this paper
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

  1998cited by this paper
• Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).

  1998cited by this paper
• Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

  1998influential reference
• Lipid lowering therapy reduces blood thrombogenicity in hypercholesterolemic patients: effect of simvastatin

  1998cited by this paper
• Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

  1998influential reference
• Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

  1998cited by this paper
• Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

  1998cited by this paper
• Correlation of angiographic morphology and clinical presentation in unstable angina.

  1997cited by this paper
• Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients

  1996cited by this paper
• Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.

  1996cited by this paper
• Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

  1995cited by this paper
• Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease.

  1995cited by this paper
• Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.

  1995influential reference
• Molecular bases of the acute coronary syndromes.

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

  1993cited by this paper
• Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor

  1992cited by this paper
• Plasma tissue plasminogen activator levels in patients with coronary heart disease.

  1988cited by this paper
• Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene.

  1987cited by this paper

• Effects of Dietary Cholesterol Regulation on Spermatogenesis of Gobiocypris rarus Rare Minnow

  2023cites this paper
• The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

  2023cites this paper
• Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients.

  2023cites this paper
• Relationship between lipoproteins, thrombosis, and atrial fibrillation

  2021cites this paper
• Pravastatin for lowering lipids.

  2020cites this paper
• Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review

  2019cites this paper
• Endothelial progenitor cells: Exploring the pleiotropic effects of statins

  2017cites this paper
• Gastrointestinal Bleeding Events and Statin Use: A Large Propensity Score-Matched Retrospective Cohort Study

  2017cites this paper
• Statins: the Panacea of Cirrhosis?

  2016cites this paper
• CARDIOLOGÍA DEL ADULTO - REVISIÓN DE TEMAS

  2016cites this paper
• Lipoproteins as modulators of atherothrombosis: From endothelial function to primary and secondary coagulation.

  2016cites this paper
• Interaction Studies of ACE Inhibitors with Statins

  2015cites this paper
• Simultaneous Determination of Cetirizine, Atorvastatin, Simvastatin, Rosuvastatin or Pravastatin in Formulations and Human Serum by RP-HPLC

  2015cites this paper
• The Safety and Benefit of Statins in Liver Cirrhosis: a Review.

  2015cites this paper
• Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.

  2015cites this paper
• Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase.

  2014cites this paper
• [Type 4a myocardial infarction].

  2014cites this paper
• Efficacy of Short‐Term High‐Dose Atorvastatin Pretreatment in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Meta‐analysis of Nine Randomized Controlled Trials

  2013cites this paper
• Statins and percutaneous coronary intervention: a complementary synergy.

  2013cites this paper
• Statins and succinylcholine interaction: A cause of concern for serious muscular damage in anesthesiology practice!

  2013cites this paper
• Effects of simvastatin administration on rodents with lipopolysaccharide‐induced liver microvascular dysfunction

  2013cites this paper
• Effects of HMG-CoA Reductase Inhibitors on Coagulation and Fibrinolysis Processes

  2012cites this paper
• A study of natural killer cells in renal failure and in patients at cardiovascular risk

  2012cites this paper
• Statins and infrainguinal vascular bypass procedures.

  2012cites this paper
• The effects of simvastatin on angiogenesis: studied by an original model of atherosclerosis and acute myocardial infarction in rabbit

  2011cites this paper
• Novel mechanistic and clinical implications concerning the safety of statin discontinuation

  2011cites this paper
• Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial

  2011cites this paper
• [Treatment update on portal hypertension and complications].

  2010cites this paper
• Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

  2010cites this paper
• Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention

  2010cites this paper
• Advances in Interventional Cardiology Periprocedural Myocardial Infarction Prevalence, Prognosis, and Prevention

  2010cites this paper
• The antiplatelet and antithrombotic actions of statins.

  2010cites this paper
• Hemostatic effects of simvastatin in subjects with impaired fasting glucose

  2010cites this paper
• Estudo da atividade inflamatória e plaquetária em pacientes com doença arterial coronária estável, submetidos a tratamento com duas estratégias hipolipemiantes intensivas: sinvastatina 80 mg e ezetimiba 10 mg/sinvastatina 20 mg

  2010cites this paper
• Statins in Portal Hypertension

  2010cites this paper
• Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.

  2009cites this paper
• Statin pleiotropism and atherosclerotic plaque rupture

  2009cites this paper
• Pleiotropic vasoprotective effects of statins: The chicken or the egg?

  2009cites this paper
• A response to the letter regarding the pleiotropic effects of fluvastatin on acute inflammatory response and the role of MMP-9 in plaque destabilization and intraplaque hemorrhage.

  2009cites this paper
• Potential therapeutic role of statins in neurological disorders

  2008cites this paper
• Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression

  2008cites this paper
• Randomized trial of statin administration for myocardial injury: is intensive lipid-lowering more beneficial than moderate lipid-lowering before percutaneous coronary intervention?

  2007cites this paper
• REVIEW: Aortic Atheromas: Current Concepts and Controversies—A Review of the Literature

  2007cites this paper
• The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.

  2007cites this paper
• Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque.

  2007cites this paper
• Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.

  2007cites this paper
• Statins: a new insight into their mechanisms of action and consequent pleiotropic effects.

  2007cites this paper
• Influence of statins on perioperative outcomes.

  2006cites this paper
• Ezetimibe: one step beyond in the battle against atherosclerosis

  2006cites this paper
• Cardiac biomarkers for the prediction and diagnosis of atherosclerotic disease and its complications.

  2006cites this paper
• Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits.

  2006cites this paper
• Statin therapy for native and peri-interventional coronary heart disease.

  2006cites this paper
• Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor

  2006cites this paper
• Low-Density Lipoprotein-Lowering Medication and Platelet Function

  2006cites this paper
• Statins Could Be Used to Control Replication of Some Viruses, Including HIV-1

  2005cites this paper
• Interindividual Differences of Response to Statin Treatment Cannot Be Explained by Variations of the Human Gene for RhoA

  2005cites this paper
• Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina.

  2005cites this paper
• [Statins and prevention of strokes].

  2005cites this paper
• Statines et prévention des accidents vasculaires cérébraux

  2005cites this paper
• Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.

  2005cites this paper
• Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction.

  2004cites this paper
• Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts.

  2004cites this paper
• Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors

  2004cites this paper
• Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.

  2004cites this paper
• Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation

  2004cites this paper
• Statin Drugs and Dietary Isoprenoids Downregulate Protein Prenylation in Signal Transduction and Are Antithrombotic and Prothrombolytic Agents

  2004cites this paper
• Recenti vedute sulla patogenesi degli stati protrombotici associati a ipercolesterolemia

  2004cites this paper
• Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury.

  2004cites this paper
• Statins in Atherothrombosis

  2004cites this paper
• Possibilities of manipulating nitric oxide biosynthesis in the treatment of portal hypertension: statins

  2004cites this paper
• Statins and Blood Coagulation

  2004cites this paper
• Chapter 8 – The Pleiotropic Effects of Statins: Relevance to Their Salutary Effects

  2004cites this paper
• CD40 Ligand: A Novel Target in the Fight against Cardiovascular Disease

  2004cites this paper
• New nonlipid effects of statins and their clinical relevance in cardiovascular disease

  2004cites this paper
• Shear stress-dependent platelet function after LDL cholesterol apheresis.

  2004cites this paper
• Chapter 12 – Anticoagulant Effects of Statins

  2004cites this paper
• Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?

  2004cites this paper
• Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study

  2004cites this paper
• Pravastatin potentiates the anticoagulant effects of low molecular weight heparin.

  2004cites this paper
• Role of Statins in the Treatment and Prevention of Stroke: Introduction

  2004cites this paper
• Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus

  2003cites this paper
• Endothelium : Signaling , Oxidative Stress , and Gene Expression

  2003cites this paper
• Long-Term Hemostatic Effects of Cholesterol-Lowering Therapy with Atorvastatin

  2003cites this paper
• Statins and Plaque Stability

  2003cites this paper
• Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

  2003cites this paper
• Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.

  2003cites this paper
• Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.

  2003cites this paper
• Statins and their role in vascular protection.

  2003cites this paper
• Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment

  2003cites this paper
• The coagulation system as a target for experimental therapy of human gliomas

  2003cites this paper
• The statins: multifunctional antithrombotic and antineoplastic drugs.

  2003cites this paper
• The effects of lipid-regulating therapy on haemostatic parameters.

  2003cites this paper
• The Statins: Multifunctional Antithrombotic and Antineoplastic Drugs

  2003cites this paper
• Endothelium-dependent effects of statins.

  2003cites this paper
• Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.

  2002cites this paper
• Do Statins Increase the Homocysteine Level

  2002cites this paper
• The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide.

  2002cites this paper
• HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins

  2002cites this paper
• Stabilization of atherosclerotic plaques: New mechanisms and clinical targets

  2002cites this paper
• Induced by Angiogenic Factors In Vitro and Angiogenesis Cerivastatin , an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase , Inhibits

  2002cites this paper